A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry
Jan Hillert, Jon A Tsai, Mona Nouhi, Anna Glaser, Tim Spelman
MULTIPLE SCLEROSIS JOURNAL | SAGE PUBLICATIONS LTD | Published : 2021
BACKGROUND: Teriflunomide and dimethyl fumarate (DMF) are first-line disease-modifying treatments for multiple sclerosis with similar labels that are used in comparable populations. OBJECTIVES: The objective of this study was to compare the effectiveness and persistence of teriflunomide and DMF in a Swedish real-world setting. METHODS: All relapsing-remitting multiple sclerosis (RRMS) patients in the Swedish MS registry initiating teriflunomide or DMF were included in the analysis. The primary endpoint was treatment persistence. Propensity score matching was used to adjust comparisons for baseline confounders. RESULTS: A total of 353 teriflunomide patients were successfully matched to 353 DM..View full abstract
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This collaborative study with the Department of Clinical Neuroscience, Karolinska Institute was funded by Sanofi.